株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

てんかん治療薬の世界市場:成長、動向、および予測

Epilepsy Drugs Market - Growth, Trends, and Forecast (2020 - 2025)

発行 Mordor Intelligence LLP 商品コード 921243
出版日 ページ情報 英文 114 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.54円で換算しております。
てんかん治療薬の世界市場:成長、動向、および予測 Epilepsy Drugs Market - Growth, Trends, and Forecast (2020 - 2025)
出版日: 2020年01月01日 ページ情報: 英文 114 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

てんかん治療薬の世界市場の主な成長要因には、過去数年間の新薬承認の増加、てんかんの症例増加、世界における病状に関する認識の向上などが挙げられます。

当レポートは世界のてんかん治療薬市場について調査しており、市場機会や動向、成長および抑制要因、治療薬・流通チャネル・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 調査の前提条件
  • 調査範囲

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概要
  • 市場成長要因
    • 過去数年間の新薬承認の増加
    • てんかんの症例増加
    • 世界におけるてんかんに関する認識の高まり
  • 市場抑制要因
    • 薬物に関連する副作用
    • 主要ブランドの最近の特許失効
  • ポーターのファイブフォース分析

第5章 市場セグメンテーション

  • 治療薬別
    • 第1世代
    • 第2世代
    • 第3世代
  • 流通チャネル別
    • 病院薬局
    • 薬局
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Abbott Laboratories
    • GlaxoSmithKline PLC
    • Johnson & Johnson Health Care Systems Inc.
    • Novartis AG
    • Pfizer, Inc.
    • Sanofi SA
    • Sunovion Pharmaceuticals Inc.
    • 武田薬品工業株式会社
    • UCB SA,

第7章 市場機会および今後の動向

目次
Product Code: 67071

Market Overview

The major factors for the growth of the epilepsy drugs market include the rise in the new drug approvals over the past few years, increasing cases of epilepsy, and raising awareness about the condition across the globe.

Epilepsy is a central nervous system (CNS) disorder in which brain activity becomes abnormal, resulting in seizures or periods of unusual behavior, and sensations. It can occur due to a genetic disorder or an acquired brain injury. According to the data published by the Epilepsy Foundation, in the United States, in 2015 around 1.2% of the population or 3 million adults had active epilepsy which was an increase from 2.3 million adults with active epilepsy in 2010. Furthermore, as per the data published by the World Health Organization (WHO) epilepsy accounts for a significant proportion of the population affecting around 50 million people worldwide. In addition to the rising cases of epilepsy, there is a rising effort taken to increase awareness about the condition. One of the organization's Epilepsy Foundation is promoting public awareness and education by undertaking research and delivering specialist medical care and support services to the people affected by epilepsy.

Scope of the Report

As per the scope of this report, epilepsy drugs do not cure epilepsy but helps to control seizures. The drugs are classified into three major segments first generation, second generation, and third generation. The market is segmented by drugs, distribution channels, and geography.

Key Market Trends

Second Generation is the Segment by Drugs expected to Hold Largest Market Share over the Forecast Period

The second-generation drugs are expected to hold the largest market share owing to the several significant advantages such as reduced drug-drug interactions, less life-threatening adverse events and less negative impact on cognitive functions. Furthermore, the rising cases of epilepsy will boost the demand for drugs in the market. Also, recently in May 2018 one of the market player UCB announced that the United States Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for its newest anti-epileptic drug (AED) BRIVIACT (brivaracetam) CV oral formulations indicated as monotherapy and adjunctive therapy in the treatment of partial-onset (focal) seizures in patients aged four years and older. Thus, owing to the new product launch and acceptance of second-generation epilepsy drugs the market is expected to witness high growth over the forecast period.

North America is Expected to Hold Largest Market Share over the Forecast Period

The United States is expected to be the largest epilepsy drug market owing to the presence of better healthcare infrastructure and rising cases of epilepsy. As per the new Morbidity and Mortality Weekly Report from the CDC, around 3.4 million people in the United States live with seizures, including 470,000 children. While, despite all available treatments, 4 out of 10 people with epilepsy continue to experience uncontrolled seizures while many more experience less than optimal seizure control. Thus, there is a rising demand for effective treatment in the region which is expected to boost the growth of the market. Furthermore, there are various organizations making awareness about epilepsy in the United States. For instance, the Epilepsy Foundation is a non-profit organization in the United States, raises public awareness to increase understanding of seizures and dispel myths. Thus, owing to the all above-mentioned factors the market is expected to witness high growth.

Competitive Landscape

The market studied is a consolidated market owing to the presence of a few major market players. Some of the market players are Abbott Laboratories, GlaxoSmithKline PLC, Johnson & Johnson Health Care Systems Inc., Novartis AG, Pfizer, Inc., Sanofi SA, Sunovion Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, and UCB S.A.,

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in the New Drug Approvals over the Past Few Years
    • 4.2.2 Increase in the Cases of Epilepsy
    • 4.2.3 Rising Awareness about the Condition across the Globe
  • 4.3 Market Restraints
    • 4.3.1 Side Effects associated with Drugs
    • 4.3.2 Recent Patent Expiration of Major Brands
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drugs
    • 5.1.1 First Generation
    • 5.1.2 Second Generation
    • 5.1.3 Third Generation
  • 5.2 By Distribution Channel
    • 5.2.1 Hospital Pharmacy
    • 5.2.2 Pharmacy Stores
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 GlaxoSmithKline PLC
    • 6.1.3 Johnson & Johnson Health Care Systems Inc.
    • 6.1.4 Novartis AG
    • 6.1.5 Pfizer, Inc.
    • 6.1.6 Sanofi SA
    • 6.1.7 Sunovion Pharmaceuticals Inc.
    • 6.1.8 Takeda Pharmaceutical Company Limited
    • 6.1.9 UCB S.A.,

7 MARKET OPPORTUNITIES AND FUTURE TRENDS